دورية أكاديمية
PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer
| العنوان: | PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer |
|---|---|
| المؤلفون: | Earl, Helena, Cameron, David, Miles, David, Wardley, Andrew, Ogburn, Emma, Vallier, Anne-Laure, Loi, Shrushma, Hiller, Louise, Dunn, Janet |
| المصدر: | In European Journal of Surgical Oncology May 2014 40(5):619-619 |
| قاعدة البيانات: | ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 07487983 |
|---|---|
| DOI: | 10.1016/j.ejso.2014.02.033 |